Nanjing BioPoint® has developed a novel, low-cost and instrument-free plasma separator based on lateral flow chromatography, the VLPlasma® device. It provides an integrated solution for separation, collection and drying of cell-free plasma from whole blood, suitable for storage and transport to central laboratories for testing，including HIV viral load (VL) testing and Serological testing for various diseases.
1. Clinical field trial conducted with 198 HIV-infected participants recruited from the University of Malay Medical Centre, Kuala Lumpur, Malaysia
2. Three arm comparative study with samples collected as DBS or using the VLPlasma® device, or fresh plasma (reference)
3. VL test run on COBAS® AmpliPrep / COBAS® TaqMan® (Roche)
* Two DBS samples and three FDPS samples failed to give results
The clinical results showed that the accuracy of VL testing was significantly improved by VLPlasma® compared with the DBS method. The results demonstrate the device has successfully obtained cell free plasma suitable for applications such as HIV viral load test.
Further Studies ：
Expanded applications of the VLPlasma® device in other infectious disease diagnostics are being explored in studies at the Burnet Institute, Melbourne, Australia, supported by the Bill & Melinda Gates Foundation (Grand Challenges Explorations, Round 20).
Patent application PCT/AU2015/050715, under exclusive license to Nanjing BioPoint Diagnostic Technology Co. Ltd., a spinoff company formed by the Burnet Institute.